| non-steroidal anti-inflammatory | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
|---|---|
| non-steroidal anti-inflammatory drug | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
| non-steroidal oestrogens | <pharmacology> Non-steroidal compounds with oestrogenic activity. (12 Dec 1998) |
| sugar-non-specific nuclease | <enzyme> An exocytoplasmic sugar-non-specific nuclease that is able to degrade linear or covalently closed circular double-stranded DNA as well as single-stranded DNA or RNA; from cyanobacterium anabaena; mw 29 kD; amino acid sequence has been determined Registry number: EC 3.1.- Synonym: nuca gene product, anabaena (26 Jun 1999) |
| diabetes mellitus, non-insulin-dependent | Diabetes characterised by the ability to survive without ketoacidosis in the absence of insulin therapy. It is usually of slow onset and patients exhibit a tendency to obesity. (12 Dec 1998) |
| drugs, non-prescription | Drugs that can be sold legally without a prescription. (12 Dec 1998) |
| lymphoma, non-hodgkin | Any of a group of malignant tumours of lymphoid tissue that differ from hodgkin disease, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumours is the absence of giant reed-sternberg cells, a characteristic of hodgkin's disease. (12 Dec 1998) |